Factors affecting cognitive functions of patients with high-grade gliomas: a systematic review

Tariq, Rabeet; Hussain, Nowal; Baqai, Muhammad Waqas Saeed

doi:10.1007/s10072-023-06673-4

Cited by 5 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No significant effect of tumor volume or hemisphere was observed in our patient cohort. However, we recognize that other factors, such as tumor location, grade, IDH1 mutation, edema, and the use of anti-epileptic drugs 30 , 85 , 86 may influence cognitive outcomes and we therefore suggest that larger sample studies should further explore such a more comprehensive model.…”

Section: Discussionmentioning

confidence: 99%

Brain network topology and its cognitive impact in adult glioma survivors

De Roeck,

Blommaert,

Dupont

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Structural brain network topology can be altered in case of a brain tumor, due to both the tumor itself and its treatment. In this study, we explored the role of structural whole-brain and nodal network metrics and their association with cognitive functioning. Fifty WHO grade 2–3 adult glioma survivors (> 1-year post-therapy) and 50 matched healthy controls underwent a cognitive assessment, covering six cognitive domains. Raw cognitive assessment scores were transformed into w-scores, corrected for age and education. Furthermore, based on multi-shell diffusion-weighted MRI, whole-brain tractography was performed to create weighted graphs and to estimate whole-brain and nodal graph metrics. Hubs were defined based on nodal strength, betweenness centrality, clustering coefficient and shortest path length in healthy controls. Significant differences in these metrics between patients and controls were tested for the hub nodes (i.e. n = 12) and non-hub nodes (i.e. n = 30) in two mixed-design ANOVAs. Group differences in whole-brain graph measures were explored using Mann–Whitney U tests. Graph metrics that significantly differed were ultimately correlated with the cognitive domain-specific w-scores. Bonferroni correction was applied to correct for multiple testing. In survivors, the bilateral putamen were significantly less frequently observed as a hub (pbonf < 0.001). These nodes’ assortativity values were positively correlated with attention (r(90) > 0.573, pbonf < 0.001), and proxy IQ (r(90) > 0.794, pbonf < 0.001). Attention and proxy IQ were significantly more often correlated with assortativity of hubs compared to non-hubs (pbonf < 0.001). Finally, the whole-brain graph measures of clustering coefficient (r = 0.685), global (r = 0.570) and local efficiency (r = 0.500) only correlated with proxy IQ (pbonf < 0.001). This study demonstrated potential reorganization of hubs in glioma survivors. Assortativity of these hubs was specifically associated with cognitive functioning, which could be important to consider in future modeling of cognitive outcomes and risk classification in glioma survivors.

show abstract

Section: Discussionmentioning

confidence: 99%

Brain network topology and its cognitive impact in adult glioma survivors

De Roeck,

Blommaert,

Dupont

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In this view, chemotherapies for brain tumours, whose target is within the brain parenchima, are likely to induce more severe CRCI, but there is a generalized lack of studies addressing the relation between chemotherapy and cognition in brain tumour patients, as reported in a recent review [24].…”

Section: Introductionmentioning

confidence: 99%

Impact of Chemotherapy With Temozolomide on Cognition in High-grade Glioma Patients: a Retrospective Single Centre Study

Abete-Fornara,

Socaciu,

Fanizzi

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose: starting from a lack of precise and coherent data in literature, aim of this work is to retrospectively study the influence of chemotherapy with Temozolomide (TMZ) on a wide series of neuropsychological functions in a population of adult high-grade glioma patients. Methods: an extensive neuropsychological battery was administered pre-operatively and after 6 (T1) and 12 months (T2) from surgery. After full recovery from surgery, TMZ was delivered concomitant to radiotherapy and, subsequently, adjuvantly for 5-day cycles per month. Parametric and non-parametric analyses were conducted to verify the influence of several aspects of chemotherapy on the adjusted scores of each cognitive test at the two post-operative follow-ups. Results: patients with a lower adjuvant TMZ dosage reported a better performance at the visual attention test at T1, and at the deductive reasoning test at T2. Undergoing more than 8 cycles of adjuvant therapy was slightly associated with a better performance at the long-term verbal memory tasks at T2. No other associations were found with the other cognitive tests and autonomy scales administered. Conclusions: TMZ proved to be a secure treatment with no negative side effects on cognition and on level of daily autonomy, even at the highest dosage used. This is a positive finding which enables clinicians to reassure patients about the absence of significant negative effects of TMZ on their daily life functioning. In this view, eventual cognitive changes during treatment might not be attributed to chemotherapy but to other events such as tumour relapse.

show abstract